LCAT

Mount Sinai Awarded Grant to Assess Music's Impact on Well-Being, Depression

Retrieved on: 
Thursday, April 27, 2023
DSM-IV codes, River Music Experience, Music, Depression, Life, Suicide, Parent, Music therapy, Calendar, Late preterm infant, Ministry of Women and Vulnerable Populations, Quality of life, National Endowment for the Arts, COVID, Mount Sinai, New York Academy of Medicine, Thought, DA, Pain, Student, Cooper Union, NEA, Patient, Risk, Third Street Music School Settlement, LCAT, Affect, Neurology, Nightclub, Entertainment, Nursing, Medicine

NEW YORK, April 27, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System Assessment of Music Experiences in Navigating Depression (AMEND Lab) at the Louis Armstrong Center for Music and Medicine has received a grant from the National Endowment for the Arts (NEA) to investigate how music and music therapy can influence mood and alter depression symptoms across vulnerable populations.

Key Points: 
  • "A cornerstone of the study is 'social prescribing,' a concept that is widely used in Europe," Dr. Loewy explained.
  • "It involves thinking of music less as a recreational activity, and more as a foundational prescription for everyday life.
  • The study will also involve working one-on-one with individuals with clinical depression to explore in depth how music therapy impacts their depression.
  • Additional partners in the NEA-funded study include Cooper Union, Third Street Music School, Young Adults Institute, and Lincoln Center Moments.

PARAGON SYSTEMS ANNOUNCES LAUNCH OF CYBERSECURITY EDUCATIONAL PARTNERSHIP

Retrieved on: 
Wednesday, March 15, 2023
Paragon, Certified Information Systems Security Professional, CISSP, Engineering, Education minister, LCAT, CompTIA, Student, Computer, University of Central Florida College of Undergraduate Studies, Rowan University, STEM, Nursing, Rowan

HERNDON, Va., March 15, 2023 /PRNewswire/ -- Paragon and its partner, DTCUBED, have collaborated with Rowan University to develop a Paragon-sponsored Certificate of Undergraduate Study in cybersecurity engineering and a Certificate of Graduate Study in cybersecurity engineering for Rowan students. Each certificate program will consist of four courses, including a mixture of required and elective courses. The certificate program seeks to prepare students for LCAT qualifications, as well as the Computing Technology Industry Association (CompTIA) Security+ exam, the Certified Information Systems Security Professional (CISSP) exam, and/or careers in cybersecurity.

Key Points: 
  • The certificate program seeks to prepare students for LCAT qualifications, as well as the Computing Technology Industry Association (CompTIA) Security+ exam, the Certified Information Systems Security Professional (CISSP) exam, and/or careers in cybersecurity.
  • "We appreciate working with Rowan University, and Pete Mauro at DTCUBED, as part of our educational outreach initiatives.
  • This collaboration will further the career opportunities for Rowan students while adding to our team of cybersecurity experts at Paragon.
  • We will be helping to better prepare a new generation of needed cybersecurity professionals, ultimately making our country safer," remarked Paragon CEO Tony Sabatino.

Boston Heart Diagnostics Launches LipidSeq™-- An NGS Test for Common Genetic Disorders of Lipid Metabolism

Retrieved on: 
Wednesday, August 17, 2022
LCAT, Robarts Research Institute, Triglyceride, Cardiovascular disease, Multimedia, Disorder, Risk, Apolipoprotein, Lists of diseases, Hypercholesterolemia, HDL, Lipid metabolism, Tangier disease, Hypertriglyceridemia, Patient, View, NGS, Kidney, Sitosterolemia, Mutation, Lipidology, Health, Disease, Health care, Pharmaceutical industry, Eurofins Scientific, Familial dysbetalipoproteinemia

This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.

Key Points: 
  • This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.
  • Boston Heart Diagnostics announces the launch of LipidSeq, a revolutionary genetic test for cardiovascular disease.
  • Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders.
  • For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/boston-heart-diagnostics-launch...

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

Retrieved on: 
Tuesday, March 29, 2022
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Journal, Reverse cholesterol transport, Internal medicine, Plasma, RCT, Dialysis, Degenerative disease, Opacity (optics), Kidney, ODD, Research, Journal of Internal Medicine, Prognosis, Kidney disease, Medicine, CEO, Health, Food, Codocyte, LPX, Sepsis, Corneal opacity, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HDL, EMA, IgG4-related ophthalmic disease, FDA, Annals of Internal Medicine, Patient, Disease, Pharmaceutical industry, LCAT, THE BIO-HDL CER-001, ABIONYX PHARMA

The designation covers both partial LCAT deficiency, presenting as Fisheye Disease, and complete LCAT deficiency presenting with renal symptoms and corneal opacities.

Key Points: 
  • The designation covers both partial LCAT deficiency, presenting as Fisheye Disease, and complete LCAT deficiency presenting with renal symptoms and corneal opacities.
  • Progression of LCAT deficiency, for which there is no approved treatment, can ultimately lead to renal failure requiring dialysis or kidney transplant, and/or to complete corneal opacification requiring transplant.
  • The European Medicines Administration (EMA) granted ODD status to CER-001 for the treatment of LCATdeficiency in July 2021.
  • Positive clinical results from CER-001 in LCAT disease have previously been published.

National Advertising Division Recommends P&G Discontinue Claim that Olay Body Wash "Improves Skin 3X Better" than the Leading Body Wash

Retrieved on: 
Wednesday, March 16, 2022
Better Business Bureau, Trial of the century, Advertising, Digital, LCAT, Hyaluronic acid, NAD, Multimedia, Skin, Procter & Gamble, Association of National Advertisers, B3, Disclosure, Unilever, Council, CARU, Privacy, Population, View, Liturgical struggle, Olay, P&G, Cosmetics, Dietary supplement

Even when the 3x improvement claim is not featured alongside other skin attributes, NAD found that the net impression is still one of general skin improvement.

Key Points: 
  • Even when the 3x improvement claim is not featured alongside other skin attributes, NAD found that the net impression is still one of general skin improvement.
  • Further, NAD determined that the disclosure "versus the leading body wash after 14 days, based on clinical moisture retention" was not sufficient to qualify the takeaway of the claim "improves skin 3X better" to clinical moisture retention.
  • For these reasons, NAD recommended that P&G discontinue the claim that Olay body wash "improves skin 3X better" than the leading body wash.
  • About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.

ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal

Retrieved on: 
Monday, October 11, 2021
Health, Research, Pharmaceutical, Science, Optical, Biotechnology, Uveitis, Health, Medicine, HDL, LCAT, Ophthalmology, Research, Lipid, IRIS, PEA, Fine chemical

ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced today that it is initiating discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology contract research, with a view to a possible strategic deal, in which IRIS Pharma's contract research business would remain separate from the biotech research and development activity and to continue to grow.

Key Points: 
  • ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced today that it is initiating discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology contract research, with a view to a possible strategic deal, in which IRIS Pharma's contract research business would remain separate from the biotech research and development activity and to continue to grow.
  • ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones.
  • Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005608/en/

ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine

Retrieved on: 
Tuesday, March 2, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, GABAA receptor positive allosteric modulators, Chemical compounds, Lipids, Enzymes, Lecithin–cholesterol acyltransferase, LCAT, Lecithin, Acyltransferase, Cholesterol, Niacin, Lecithin cholesterol acyltransferase deficiency

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in the LCAT (lecithin-cholesterol acyltransferase) deficiency disease published in the Annals of Internal Medicine.

Key Points: 
  • ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in the LCAT (lecithin-cholesterol acyltransferase) deficiency disease published in the Annals of Internal Medicine.
  • The patient was treated with CER-001, an apoA-I-containing HDL mimetic, to help in preventing rapidly progressive kidney failure.
  • The publication mentions positive extra-renal clinical results and the disappearance of visual blurring secondary to corneal deposits.
  • Cyrille Tupin, Managing Director of ABIONYX Pharma concludes: This represents an important step forward in the clinical development of CER-001, an HDL mimetic.